Drug Information

Drug General Information
Drug ID
D0C2IA
Former ID
DIB014301
Drug Name
DPC-168
Indication Allergic rhinitis [ICD9: 472.0, 477, 995.3; ICD10:J00, J30, J31.0, T78.4] Discontinued in Phase 1 [547358]
Company
Bristol-Myers Squibb Pharma Co
Structure
Download
2D MOL

3D MOL
Canonical SMILES
S(=O)(=O)(c1ccccc1)O.C(=O)(N[C@H]1[C@H](CN2C[C@H](Cc3cc<br />c(F)cc3)CCC2)CCCC1)Nc1cc(C(=O)C)ccc1
Target and Pathway
Target(s) C-C chemokine receptor type 3 Target Info Antagonist [528777]
KEGG Pathway Cytokine-cytokine receptor interaction
Chemokine signaling pathway
Viral carcinogenesis
NetPath Pathway IL3 Signaling Pathway
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Reactome Chemokine receptors bind chemokines
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
IL1 and megakaryotyces in obesity
IL-3 Signaling Pathway
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 547358Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015460)
Ref 528777CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2992-7. Epub 2007 Mar 24.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.